Medicine and Dentistry
Atypical Hemolytic Uremic Syndrome
100%
Disease
83%
Glioblastoma
71%
Complement Activation
64%
Eculizumab
61%
Complement Component C5b
46%
Glycosylphosphatidylinositol
45%
Radiosensitization
44%
In Vitro
43%
Radiation Therapy
34%
Complement Alternative Pathway
31%
Congenital Malformation
29%
Hypotonia
29%
Exome Sequencing
27%
Neoplasm
27%
Platelet
26%
Elevated Transaminases
26%
Xenograft
25%
Brain Cancer
24%
Gene Mutation
24%
Flank
24%
Paroxysmal Nocturnal Hemoglobinuria
24%
Complement Inhibition
24%
Germline Mutation
22%
Genome Sequencing
22%
Severe Acute Respiratory Syndrome Coronavirus 2
22%
Gene Therapy
22%
Complement Component C1s Inhibitor
22%
Induced Pluripotent Stem Cell
22%
HELLP Syndrome
22%
Clinician
22%
Solid Malignant Neoplasm
22%
Ex Vivo
22%
Pembrolizumab
22%
Nerve Cell Differentiation
22%
DNA Mismatch Repair
22%
Low Drug Dose
22%
Tirapazamine
22%
Dysmorphic Feature
22%
Microsatellite Instability
22%
Caspase 8
22%
Cell Killing
20%
Complement Inhibitor
20%
Thrombotic Thrombocytopenic Purpura
20%
End Organ Damage
15%
Glycosylphosphatidylinositol Anchored Protein
14%
Whole Genome Sequencing
14%
Intracranial Tumor
14%
Surgery
13%
Epileptic Seizure
12%
Keyphrases
GPI-anchored Protein (GPI-AP)
66%
Germline mutation
46%
Gene Therapy
44%
Induced Pluripotent Stem Cells (iPSCs)
44%
Human Malignant Glioma
44%
Radiation Therapy
40%
Alternative Complement Pathway
40%
Human Embryonic Stem Cells (hESCs)
34%
Atypical Hemolytic Uremic Syndrome (aHUS)
28%
Paroxysmal Nocturnal Hemoglobinuria
24%
Hematopoietic Stem Cells
24%
Germ Cells
24%
Complement Inhibition
24%
Elevated Liver Enzymes
22%
Tumor Model
22%
Self-renewal
22%
Primordial Germ Cells
22%
Radiosensitive
22%
COVID-19 Patients
22%
Syngeneic Mice
22%
Neoadjuvant
22%
Universal System
22%
Primary Brain Tumor
22%
Pig-a
22%
Direct Reprogramming
22%
Radiation-inducible
22%
Caspase-3 Gene
22%
Fibroblast Growth Factor 1 (FGF1)
22%
Complement Blockade
22%
Catastrophic APS
22%
Complement Dysregulation
22%
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
22%
C1 Esterase Inhibitor
22%
Hemangioblast
22%
Activin
22%
IUdR
22%
Protein Pathway
22%
Bone Morphogenic Protein
22%
Local Delivery
22%
Genetic Engineering
22%
COVID-19 Mortality
22%
Severe COVID-19
22%
Radio
22%
Factor D Inhibitor
22%
Human Pluripotent Stem Cells (hPSCs)
22%
Neonatal Lethality
22%
Malignant Glioma Cells
22%
Anchoring Proteins
22%
Anti-PD-1
22%
Frameshift mutation
22%
Biochemistry, Genetics and Molecular Biology
Glycosylphosphatidylinositol
99%
Induced Pluripotent Stem Cell
88%
Embryonic Stem Cell
56%
Phosphatidylinositol
51%
Stem Cell
50%
Germline Mutation
46%
PIGA
44%
Hemangioblast
44%
Anabolism
38%
Thrombotic Thrombocytopenic Purpura
35%
Hematopoietic Stem Cell
25%
Intellectual Disability
24%
Complement Activation
24%
Gene Mutation
22%
Hemocyte
22%
Reprogramming
22%
Activin
22%
Nerve Cell Differentiation
22%
C1-Inhibitor
22%
Fibroblast Growth Factor
22%
Frameshift Mutation
22%
Mouse Model
22%
Angiotensin-Converting Enzyme
22%
Platelet
22%
Elevated Transaminases
22%
Bone Morphogenetic Protein
22%
Cytometry by Time of Flight
16%
CD59
16%
Surface Property
16%
Cell Viability
14%
Flow Cytometry
14%
CD34
12%
Embryoid Body
12%
Serum (Blood)
11%
Lipopolysaccharide
11%
Cell Killing
11%
Mass Cytometry
11%
Mouse
11%
Sialidase
11%
Neuraminidase
11%
Shiga Toxin
11%
Naja
11%
Factor D
11%
SOX2
9%
Transfection
8%
Stem Cell Line
8%
Basic Fibroblast Growth Factor
8%
Cardiac Muscle Cell
8%
Hematopoiesis
7%
Knockout Model
7%
